文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

氟哌啶醇治疗ICU患者谵妄

Haloperidol for the Treatment of Delirium in ICU Patients.
PubMed 文献 · N Engl J Med · 2022-10-26
一句话结论在ICU谵妄成人患者中,氟哌啶醇治疗未使90天存活且出院天数较安慰剂显著增加(调整均差2.9天,95%CI -1.2至7.0,P=0.22)。

这项多中心、盲法、安慰剂对照试验纳入1000例因急性病症入住ICU的成人谵妄患者,随机接受静脉氟哌啶醇(2.5 mg 每日3次,必要时加用2.5 mg,每日最大总量20 mg)或安慰剂。主要终点90天存活且出院天数在氟哌啶醇组为35.8天(95%CI 32.9-38.6),安慰剂组为32.9天(95%CI 29.9-35.8),调整均差2.9天(95%CI -1.2至7.0,P=0.22),未达统计学显著。90天死亡率氟哌啶醇组36.3% vs 安慰剂组43.3%(调整绝对差-6.9个百分点,95%CI -13.0至-0.6)。严重不良反应氟哌啶醇组11例、安慰剂组9例。

要点

  • ICU谵妄成人患者中,氟哌啶醇组90天存活且出院天数35.8天 vs 安慰剂组32.9天,调整均差2.9天(95%CI -1.2至7.0),P=0.22,未达统计学显著。
  • 90天死亡率氟哌啶醇组36.3% vs 安慰剂组43.3%,调整绝对差-6.9个百分点(95%CI -13.0至-0.6)。
  • 严重不良反应氟哌啶醇组11例 vs 安慰剂组9例。
  • 氟哌啶醇用法为静脉2.5 mg 每日3次,必要时加用2.5 mg,每日最大总量20 mg,谵妄持续期间及复发时按需给药。
  • 研究纳入因急性病症入住ICU的成人谵妄患者,共1000例随机分组(氟哌啶醇组510例、安慰剂组490例)。

适用人群与场景

  • 因急性病症入住ICU的成人谵妄患者(纳入标准);共1000例随机分组,氟哌啶醇组510例、安慰剂组490例。

处置流程与药物剂量

  • 氟哌啶醇组:静脉氟哌啶醇2.5 mg 每日3次,必要时加用2.5 mg,每日最大总量20 mg;在ICU内谵妄持续期间给药,并按需用于复发。
  • 安慰剂组:给予安慰剂,给药方式与氟哌啶醇组相同。

研究设计与关键结果

  • 多中心、盲法、安慰剂对照试验;1000例随机(氟哌啶醇组510例、安慰剂组490例);987例(98.7%)纳入最终分析(氟哌啶醇组501例、安慰剂组486例);主要终点数据可得963例(97.6%)。
  • 主要终点90天存活且出院天数:氟哌啶醇组均值35.8天(95%CI 32.9-38.6)vs 安慰剂组32.9天(95%CI 29.9-35.8),调整均差2.9天(95%CI -1.2至7.0),P=0.22。
  • 90天死亡率:氟哌啶醇组36.3% vs 安慰剂组43.3%,调整绝对差-6.9个百分点(95%CI -13.0至-0.6)。
  • 严重不良反应:氟哌啶醇组11例 vs 安慰剂组9例。

证据类型、等级与局限

  • 证据类型:多中心、盲法、安慰剂对照随机试验(AID-ICU,ClinicalTrials.gov NCT03392376;EudraCT 2017-003829-15)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:在ICU谵妄患者中,氟哌啶醇治疗未使90天存活且出院天数较安慰剂显著增加。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Haloperidol is frequently used to treat delirium in patients in the intensive care unit (ICU), but evidence of its effect is limited.

METHODS: In this multicenter, blinded, placebo-controlled trial, we randomly assigned adult patients with delirium who had been admitted to the ICU for an acute condition to receive intravenous haloperidol (2.5 mg 3 times daily plus 2.5 mg as needed up to a total maximum daily dose of 20 mg) or placebo. Haloperidol or placebo was administered in the ICU for as long as delirium continued and as needed for recurrences. The primary outcome was the number of days alive and out of the hospital at 90 days after randomization.

RESULTS: A total of 1000 patients underwent randomization; 510 were assigned to the haloperidol group and 490 to the placebo group. Among these patients, 987 (98.7%) were included in the final analyses (501 in the haloperidol group and 486 in the placebo group). Primary outcome data were available for 963 patients (97.6%). At 90 days, the mean number of days alive and out of the hospital was 35.8 (95% confidence interval [CI], 32.9 to 38.6) in the haloperidol group and 32.9 (95% CI, 29.9 to 35.8) in the placebo group, with an adjusted mean difference of 2.9 days (95% CI, -1.2 to 7.0) (P = 0.22). Mortality at 90 days was 36.3% in the haloperidol group and 43.3% in the placebo group (adjusted absolute difference, -6.9 percentage points [95% CI, -13.0 to -0.6]). Serious adverse reactions occurred in 11 patients in the haloperidol group and in 9 patients in the placebo group.

CONCLUSIONS: Among patients in the ICU with delirium, treatment with haloperidol did not lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo. (Funded by Innovation Fund Denmark and others; AID-ICU ClinicalTrials.gov number, NCT03392376; EudraCT number, 2017-003829-15.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Andersen-Ranberg NC, Poulsen LM, Perner A, et al. Haloperidol for the Treatment of Delirium in ICU Patients. N Engl J Med. 2022. PMID: 36286254. doi:10.1056/NEJMoa2211868

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。